Tetra Bio-Pharma expects to generate over C$47.5M from DanCann Pharma distribution deal

Tetra Bio-Pharma Inc (TSE:TBP) (OTCMKTS:TBPMF) (FRA:JAM1) has struck a definitive deal with Danish biopharma DanCann Pharma for the distribution of three of its products in the Nordics and Germany, which is expected to generate over C$47.5 million in revenue for the Canadian biotech.  The deal is for the exclusive distribution of Reduvo Adversa, QIXLEEF and ENJOUCA in Denmark, Norway, Sweden, Finland, and Germany.  It includes upfront and milestone payments of up to C$1,5 million and the cumulative royalties on DanCann's sales are expected to come in at more than C$46 million.  READ: Tetra Bio-Pharma to reactivate clinical trial to evaluate veterinary drug PPP-003v to treat indolent corneal ulcers in companion animals "Both organizations strongly believe that cannabinoid-derived medicines will help improve the quality of life of patients suffering from pain and chemotherapy-induced nausea and vomiting (CINV)," said CEO at Tetra Bio-Pharma, Guy Chamberland. "This partnership will strengthen our business model and demonstrates that Tetra keeps delivering on our commitment to shareholders to monetize our assets and transitioning from a pre-revenue biopharma company to an in-revenue biopharma company," he added. DanCann Pharma's chief commercial officer (CCO) John Morell Frellsen added: "We have very high expectations for the collaboration with Tetra Bio-Pharma. "They have a unique portfolio within the pain management and CINV segments, and we look forward to introducing these lines to our markets. We have mutual expectations for the sales to commence during the first half of 2022.  DanCann Pharma estimates reaching peak sales of C$67 - 81 million by 2028, depending on the development of the markets." Reduvo Adversa is delivered via an innovative mucoadhesive-tablet system and is for the treatment of patients living with CINV as well as those suffering from AIDS-related anorexia. QIXLEEF is a botanical cannabinoid-derived medicine indicated for advanced cancer pain and breakthrough pain. It is anticipated to become the first prescription drug product for this class to be dispensed through pharmacies and prescribed by healthcare professionals. Finally, ENJOUCA is a medicinal cannabis therapeutic option (non-registered), which will help European patients manage pain, said Tetra-Bio. Tetra Bio-Pharma is focused on cannabinoid-derived drug discovery and development and has an FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. On May 4, it announced it would reactivate a clinical trial to evaluate the safety, tolerability, and potential efficacy of its veterinary ophthalmic drug PPP-003v as a treatment of indolent corneal ulcers in companion animals. It came after the firm received authorization from the Veterinary Drugs Directorate of Health Canada for a one-year extension to continue the clinical trial. Contact the author at giles@proactiveinvestors.com